Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 1,263 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Copd Clear all
Completed Phase 3 Interventional Results available

A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT05573464
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
BGF MDI HFO 320/14.4/9.6 μg, BGF MDI HFA 320/14.4/9.6 μg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
20
States / cities
Phoenix, Arizona • Newport Beach, California • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 25, 2026, 4:28 PM EDT
Completed Not applicable Interventional

Fish Oil and HMB Supplementation in COPD

NCT03796455
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Capsule + Powder supplementation, stable tracer infusion
Dietary Supplement · Other
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years to 100 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 25, 2026, 4:28 PM EDT
Completed Phase 4 Interventional

Chronic Obstructive Pulmonary Disease Endpoints Study

NCT00358358
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Propionate/Salmeterol 500/50mcg combination, Fluticasone Propionate 500mcg, Salmeterol 50mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Absecon, New Jersey • Charleston, South Carolina • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 25, 2026, 4:28 PM EDT
Completed Phase 3 Interventional Results available

Effect of Ensifentrine Treatment on CAT Score

NCT06460493
View directory record Official record
Conditions
COPD
Interventions
Ensifentrine 3 mg twice daily
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 25, 2026, 4:28 PM EDT
Completed Not applicable Interventional

A Study of Tobacco Smoke and Children With Respiratory Illnesses

NCT03062709
View directory record Official record
Conditions
Bronchiolitis, Pneumonia, Reactive Airway Disease, Asthma, Tobacco Smoking, Tobacco Cessation, Bronchopulmonary Dysplasia
Interventions
Breathe Easy Coalition written materials, Maine Tobacco Helpline, Urine cotinine testing
Behavioral · Diagnostic Test
Lead sponsor
MaineHealth
Other
Eligibility
Up to 10 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 25, 2026, 4:28 PM EDT
Not listed No phase listed Observational

Vibration Response Imaging (VRI) in Dyspnea Patients Presenting to the ED

NCT01206621
View directory record Official record
Conditions
Dyspnea
Interventions
Not listed
Lead sponsor
Deep Breeze
Industry
Eligibility
41 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
7
States / cities
Newark, Delaware • Las Vegas, Nevada • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 13, 2011 · Synced Oct 25, 2026, 4:28 PM EDT
Completed Phase 2 Interventional Results available

ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD

NCT00801684
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Placebo, TrIP-2D, TrIP-2SS, TrIP-2SS + Foradil
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 19, 2011 · Synced Oct 25, 2026, 4:28 PM EDT
Completed Not applicable Interventional Results available

Telehealth Pulmonary Rehabilitation for Hispanic and African-American Patients Admitted With Exacerbation of COPD

NCT03007485
View directory record Official record
Conditions
COPD Exacerbation
Interventions
Telehealth Pulmonary Rehabilitation
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 25, 2026, 4:28 PM EDT
Completed Phase 2 Interventional

Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination

NCT01321463
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
PH-797804, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 80 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
22
States / cities
Mobile, Alabama • Glendale, Arizona • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Oct 25, 2026, 4:28 PM EDT
Completed No phase listed Observational

Dysbiosis Impact on Lung Disease in HIV

NCT04155684
View directory record Official record
Conditions
HIV Infections, COPD, Microbiome
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 25, 2026, 4:28 PM EDT
Completed No phase listed Observational

An Exploratory, Observational, Non-interventional, Open Label, Remote Pilot Study to Assess Adherence in COPD Subjects

NCT03745547
View directory record Official record
Conditions
Moderate Chronic Obstructive Pulmonary Disease, Severe Chronic Obstructive Pulmonary Disease
Interventions
Adherence to wearing a Spire wearable health monitor
Other
Lead sponsor
Spire, Inc.
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2021 · Synced Oct 25, 2026, 4:28 PM EDT
Completed Phase 3 Interventional

A Comparison of the Effects of Tiotropium Inhalation qd and Salmeterol Inhalation Bid on Arterial Blood Gases.

NCT00274534
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Salmeterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
50 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
2
States / cities
Hines, Illinois • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Oct 25, 2026, 4:28 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Palliative Care Health Literacy Education and QOL Compared to Usual Care

NCT06089499
View directory record Official record
Conditions
COPD
Interventions
Get Palliative Care: four educational learning module videos
Behavioral
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
65 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 25, 2026, 4:28 PM EDT
Terminated Not applicable Interventional

AIRVO Device Intervention for Moderate to Severe COPD

NCT04576936
View directory record Official record
Conditions
COPD, COPD Exacerbation
Interventions
AIRVO
Other
Lead sponsor
Renown Health
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 25, 2026, 4:28 PM EDT
Completed No phase listed Observational Results available

Comparative Effectiveness of Telemedicine in Primary Care

NCT04684836
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure, Diabetes, Hypertension
Interventions
Exposure to telemedicine, after the onset of the pandemic
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
19 Years and older
Enrollment
33,100 participants
Timeline
2021 – 2022
U.S. locations
4
States / cities
Gainesville, New York • New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 25, 2026, 4:28 PM EDT
Completed Phase 3 Interventional Results available

A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation

NCT01682863
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
QVA149, QAB149, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
47
States / cities
Vestavia Hills, Alabama • Huntington Beach, California • Lakewood, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Oct 25, 2026, 4:28 PM EDT
Completed Phase 2 Interventional Results available

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis

NCT04631016
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Chronic Bronchitis
Interventions
Tozorakimab, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
16
States / cities
Sheffield, Alabama • Newport Beach, California • Newark, Delaware + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 25, 2026, 4:28 PM EDT
Completed No phase listed Observational

Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD)

NCT01419158
View directory record Official record
Conditions
Alpha-1 Antitrypsin Deficiency, Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
Alpha-1 Foundation
Other
Eligibility
18 Years and older
Enrollment
3,457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
18
States / cities
Los Angeles, California • Denver, Colorado • Gainesville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2012 · Synced Oct 25, 2026, 4:28 PM EDT
Completed Phase 3 Interventional

Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients

NCT00274508
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium bromide
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 75 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
4
States / cities
Boston, Massachusetts • Rochester, Minnesota • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 25, 2026, 4:28 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of QVA149 in COPD Patients

NCT02487446
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
QVA149, Umeclidinium/vilanterol, Placebo (umeclidinium/vilanterol), Placebo (QVA149)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
58
States / cities
Andalusia, Alabama • Anniston, Alabama • Jasper, Alabama + 52 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 25, 2026, 4:28 PM EDT
Completed Phase 4 Interventional

Effectiveness and Cost Impact of a Telecommunications System in COPD

NCT00012805
View directory record Official record
Conditions
Lung Diseases, Obstructive
Interventions
Telephone Monitoring
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 25, 2026, 4:28 PM EDT
Completed Not applicable Interventional

Multicomponent Intervention to Decrease Chronic Obstructive Pulmonary Disease (COPD)-Related Hospitalizations

NCT01058486
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Self-Management and Motivational Interviewing
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Rochester, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 25, 2026, 4:28 PM EDT
Completed Not applicable Interventional Results available

Home Pulmonary Rehabilitation for COPD

NCT03480386
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Emphysema
Interventions
Home Based Pulmonary Rehabilitation
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 99 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Jacksonville, Florida • Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Oct 25, 2026, 4:28 PM EDT
Not listed Phase 2 Interventional

Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, and the Effect of SCIgR for Prevention

NCT05764993
View directory record Official record
Conditions
COPD Exacerbation Acute
Interventions
CUVITRU - Ig subcutaneous human 20%, Standard Medical Therapy
Biological · Other
Lead sponsor
Rochester General Hospital
Other
Eligibility
18 Years to 82 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 25, 2026, 4:28 PM EDT